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PHENOTYPIC CONVERGENCE OF MENKES AND
WILSON DISEASE
Menkes disease is an X-linkedmultisystem disorder with
epilepsy, kinky hair, and neurodegeneration caused by
mutations in the copper transporter ATP7A. Other
ATP7Amutations have been linked to juvenile occipital
horn syndrome and adult-onset hereditary motor neu-
ropathy.1,2 About 5%–10% of the patients present with
“atypical Menkes disease” characterized by longer
survival, cerebellar ataxia, and developmental delay.2
The intracellular copper transport is regulated by 2 P
type ATPase copper transporters ATP7A and ATP7B.
These proteins are expressed in the trans-Golgi network
that guides copper to intracellular compartments, and in
copper excess, it relocates copper to the plasma
membrane to pump it out from the cells.3 ATP7B
mutations cause Wilson disease with dystonia, ataxia,
tremor, and abnormal copper accumulation in the
brain, liver, and other organs.4
Here, we report an ATP7A mutation, manifesting
with an unusual complex phenotype resemblingWilson
disease.
Methods. A 29-year-old man was born to
a nonconsanguineous family; his father and paternal
uncle suffer from genetically confirmed X-linked
Kennedy disease. He achieved normal developmental
milestones and manifested with progressive gait ataxia
and proximal and distal leg weakness with early teens
onset. Four limb spasticity evolved with extrapyramidal
movement disorder, and he started using wheelchair at
the age of 20. Clinical examination detected normal
stature with no skeletal and joint changes and
no connective tissue, cardiovascular, or hepatic
abnormalities. He had normal vision and no evidence
of Kayser-Fleischer rings, but bilateral nystagmus was
present. He had severe spasticity and dystonia in all
four extremities. Deep tendon reflexes were increased
(41) except for absent ankle jerks; clonus was present;
and Babinski sign was positive. Cerebellar symptoms
associated include intention tremor, dysmetria, and
dysdiadochokinesis, and Romberg test was positive. His
gait was spastic-ataxic (figure, A and C). He had
dysarthria but preserved cognition and no mental
illness. Routine laboratory investigations were normal.
Metabolic tests including coeruloplasmin (0.19 g/L)
and copper in serum and urine were repeatedly
normal. EMG of the left tibial anterior muscle revealed
increased insertional activity with fibrillations and larger
motor units. Nerve conduction velocities were normal,
but amplitudes were reduced in the peroneal and medial
nerves, suggesting axonal motor neuropathy. Initial brain
MRI at 9 years of age indicated high signal intensity of
bilateral globus pallidus on T2-weighed images. Follow-
up scan at age 29 years showed mildly increased signal
intensity of bilateral globus pallidus on fluid-attenuated
inversion recovery (FLAIR) sequences but not on T2-
weighed images and mild cerebellar atrophy (figure, B).
Genetic testing was negative for Kennedy disease
and common ataxias. Illumina TruSeq 62 Mb exome
capture, sequencing (100 bp paired-end reads, HiSeq
2000; Illumina, San Diego, CA), and alignment
(UCSC hg19) was performed in the patient. Poten-
tially deleterious recessive or X-linked variants were
identified using QIAGEN Ingenuity Variant Analysis
and validated by Sanger sequencing. Immunoblotting
was performed using standard protocols.1
Results. The patient carried the hemizygous
c.2279A.G, p.(Tyr760Cys) variant in ATP7A. His
healthy mother was heterozygous for the sequence
change which was absent in her healthy brother. The
variant was rare (Exome Aggregation Consortium: 4 in
87,766 heterozygous X chromosomes, no hemizygous),
predicted highly deleterious by 5 different prediction
tools, and affected a highly conserved residue in the
third transmembrane domain of ATP7A. The neigh-
boring p.(Ser761Pro) has been associated with the mod-
erate Menkes phenotype.2 Immunoblotting confirmed
severely reduced ATP7A protein in the patient’s fibro-
blasts compared with the control (figure, D).
Discussion. We identified the c.2279A.G,
p.(Tyr760Cys) ATP7A variant in a patient with com-
plex neurologic signs of spastic tetraparesis, ataxia, dys-
tonia, and axonal motor neuropathy. The mutation
segregated with the disease in the family and resulted
in reduced ATP7A protein. Smaller amounts of func-
tional ATP7A have been reported as sufficient to cause
milder phenotypes.1 However, the association of spas-
tic tetraparesis, ataxia, dystonia, and axonal motor neu-
ropathy observed in our patient is remarkably different
from any of the phenotypes reported with mutations in
ATP7A. Wilson disease presents with heterogeneous
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hepatic and/or neurologic presentation, including vari-
able combinations of dystonia, cerebellar, extrapyrami-
dal, or psychiatric symptoms.4 White matter lesions and
cerebral atrophy are seen in mild Menkes disease, but
T2-weighted high signal intensities, indicating abnormal
copper deposition in the globus pallidus, are more
characteristic for Wilson disease, a copper retention
disorder caused by ATP7B mutations.4 ATP7A variants
as modifiers have been studied in Wilson disease based
on a recent canine model carrying mutations in either
ATP7A or ATP7B.5 The 2 proteins share sequence
homology for residues involved in copper translocation,
regardless of their directionally different trafficking. A 38
amino acid segment within the third transmembrane
domain is implicated in the trans-Golgi retention of
ATP7A.6 This same region is mutated in our patient
suggesting subsequent ATP7A mislocalisation and
misfolding in the disease mechanism. It is possible
that the mutation triggers conformational changes and
induces aberrant protein-protein interactions leading to
impaired ATP7A trafficking.3
Our case supports the large phenotypic variability
of ATP7Amutations and highlights that deficiency of
the two copper transporter ATPases may cause over-
lapping phenotypes. ATP7A seem to be a human dis-
ease gene with very variable clinical presentations, and
better understanding of these phenotypes may point
to mechanistic overlap with other copper metabolism
disorders, e.g., aceruloplasminemia. We recommend
genetic screening for ATP7A mutations in patients
who manifest clinical symptoms of Wilson disease
without mutations in ATP7B.
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Figure Clinical presentation, neuroimaging, and immunoblotting
(A) Photograph of the patient illustrates spasticity. (B) Neuroimages indicate bilateral abnormal signal intensity in the globus
pallidus (T2, fluid-attenuated inversion recovery) andmild cerebellar atrophy (T1). (C) Leading clinical symptoms. (D) Immunoblot
analysis detected severely reduced ATP7A protein in the patient’s fibroblasts.
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